GH RESEARCH PLC

$19.26 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About GH RESEARCH PLC

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. It focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The Company is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

Stock Analysis

last close $19.26
1-mo return -21.6%
3-mo return -12.5%
avg daily vol. 125.65T
52-week high 30.43
52-week low 12.38
market cap. $1.2B
forward pe -
annual div. -
roe -14.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 54.9%
baraka

Subscribe now for daily local and international financial news

Subscribe